Orlistat (also known as tetrahydrolipstatin) is a drug designed to treat obesity. It is marketed as a prescription drug under the trade name Xenical by Roche in most countries, and is sold over-the-counter as Alli[2] by GlaxoSmithKline in the United Kingdom and the United States.[3] Its primary function is preventing the absorption of fats from the human diet by acting as a lipase inhibitor, thereby reducing caloric intake. It is intended for use in conjunction with a healthcare provider-supervised reduced-calorie diet.[4]
Starting at
(S)-((S)-1-((2S,3S)-3-Hexyl-4-oxooxetan-2-yl)tridecan-2-yl) 2-formamido-4-methylpentanoate |
Trade names | Xenical, alli |
AHFS/Drugs.com | monograph |
MedlinePlus | a601244 |
Licence data | EMA:Link, US FDA:link |
Pregnancy category |
AU: B1 US: X (Contraindicated) |
Legal status |
AU: S3 (Pharmacist only) UK: Pharmacy medicines US: OTC |
Routes of administration |
Oral |
Bioavailability | Negligible[1] |
Protein binding | >99% |
Metabolism | In the GI tract |
Biological half-life | 1 to 2 hours |
Excretion | Fecal |
CAS Number | 96829-58-2 |
ATC code | A08AB01 |
PubChem | CID: 3034010 |
IUPHAR/BPS | 5277 |
DrugBank | DB01083 |
ChemSpider | 2298564 |
UNII | 95M8R751W8 |
KEGG | D04028 |
ChEMBL | CHEMBL175247 |
Formula | C29H53NO5 |
Molecular mass | 495.735 g/mol |
SMILES[show] |
|
InChI[show] |